MICHAEL TUSHLA: Open Payments
NPI 1811076961 · SANTA PAULA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,109 in 40 payments from 12 companies in 2025. Trend: 2023 $555 · 2024 $577 · 2025 $1,109
Food & beverage: $934Consulting: $175
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $264 |
| AstraZeneca Pharmaceuticals LP | 12 | $221 |
| Novo Nordisk Inc | 7 | $170 |
| Alnylam Pharmaceuticals Inc. | 1 | $139 |
| Dexcom, Inc. | 3 | $89 |
| Radius Health, Inc. | 2 | $58 |
| Exact Sciences Corporation | 2 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| Eisai Inc. | 1 | $23 |
| PFIZER INC. | 1 | $21 |
Products named: PROLIA, AMVUTTRA, AIRSUPRA, Ozempic, Dexcom G6 Transmitter, BREZTRI, Tymlos, Cologuard Collection Kit.
Industry payments across CA — which companies pay providers there.
